United Therapeutic(UTHR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low532.59
Day High555.23
Open:551.98
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM)
Motley Fool
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns
MarketBeat
These 3 Stocks Lowered Their Share Counts Drastically in Q1
MarketBeat.com
Tipranks
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)
StockStory
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
VSTS
Motley Fool
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
Tipranks
PHINDER Trial Update: How Earlier Pulmonary Hypertension Screening Could Shape United Therapeutics’ Market
StockStory
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down
NVMI
Tipranks
United Therapeutics Advances High-Risk, High-Reward Xenokidney Trial for ESRD
Tipranks
Analysts’ Top Healthcare Picks: United Therapeutics (UTHR), Sino Biopharmaceutical (SBMFF)
Tipranks
J.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)
Tipranks
Jefferies Remains a Buy on United Therapeutics (UTHR)
Tipranks
TD Cowen Reaffirms Their Buy Rating on United Therapeutics (UTHR)
StockStory
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
UTHR
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Brookdale Senior Living (BKD)
Tipranks
United Therapeutics’ Earnings Call Signals Next Growth Phase
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
StockStory
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
UTHR
Motley Fool
UTHR Q1 2026 Earnings Transcript

Profile

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.